Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2011-03-29
2011-03-29
Saunders, David A (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C424S001530, C424S001690, C424S009300, C424S009400, C424S009500, C424S009600, C424S136100, C514S021800, C514S021900, C530S330000, C530S387300, C530S408000, C530S409000
Reexamination Certificate
active
07914787
ABSTRACT:
The present invention relates to a bi-specific antibody or antibody fragment having at least one arm that specifically binds a targeted tissue and at least one other arm that specifically binds a targetable construct. The targetable construct comprises a carrier portion which comprises or bears at least one epitope recognizable by at least one arm of said bi-specific antibody or antibody fragment. The targetable construct further comprises one or more therapeutic or diagnostic agents or enzymes. The invention provides constructs and methods for producing the bi-specific antibodies or antibody fragments, as well as methods for using them.
REFERENCES:
patent: 3933592 (1976-01-01), Clendenning
patent: 4468457 (1984-08-01), Goldenberg et al.
patent: 4735210 (1988-04-01), Goldenberg
patent: 4737453 (1988-04-01), Primus
patent: 4792521 (1988-12-01), Shochat
patent: 4818709 (1989-04-01), Primus et al.
patent: 4863713 (1989-09-01), Goodwin et al.
patent: 4971792 (1990-11-01), Steplewski et al.
patent: 5078998 (1992-01-01), Bevan et al.
patent: 5101827 (1992-04-01), Goldenberg
patent: 5128119 (1992-07-01), Griffiths
patent: 5143715 (1992-09-01), Barnhart
patent: 5183756 (1993-02-01), Schlom
patent: 5225541 (1993-07-01), Hackett et al.
patent: 5274076 (1993-12-01), Barbet et al.
patent: 5328679 (1994-07-01), Hansen et al.
patent: 5469854 (1995-11-01), Unger et al.
patent: 5502037 (1996-03-01), Kondratyev
patent: 5503987 (1996-04-01), Wagner et al.
patent: 5534254 (1996-07-01), Huston
patent: 5534326 (1996-07-01), Huston et al.
patent: 5591828 (1997-01-01), Bosslet et al.
patent: 5683694 (1997-11-01), Bagshawe et al.
patent: 5686578 (1997-11-01), Goldenberg
patent: 5693762 (1997-12-01), Queen et al.
patent: 5697902 (1997-12-01), Goldenberg
patent: 5716595 (1998-02-01), Goldenberg
patent: 5746996 (1998-05-01), Govindan et al.
patent: 5753206 (1998-05-01), McBride et al.
patent: 5772981 (1998-06-01), Govindan et al.
patent: 5776093 (1998-07-01), Goldenberg
patent: 5776094 (1998-07-01), Goldenberg
patent: 5776095 (1998-07-01), Goldenberg
patent: 5837242 (1998-11-01), Holliger et al.
patent: 5837243 (1998-11-01), Deo et al.
patent: 5851527 (1998-12-01), Hansen
patent: 5959083 (1999-09-01), Bosslet et al.
patent: 6010680 (2000-01-01), Govindan et al.
patent: 6077499 (2000-06-01), Griffiths et al.
patent: 6096289 (2000-08-01), Goldenberg
patent: 6121424 (2000-09-01), Whitlow et al.
patent: 6126916 (2000-10-01), McBride et al.
patent: 6187284 (2001-02-01), Griffiths
patent: 6540980 (2003-04-01), Blumenthal et al.
patent: 6962702 (2005-11-01), Hansen et al.
patent: 7074405 (2006-07-01), Hansen et al.
patent: 7138103 (2006-11-01), Goldenberg et al.
patent: 7560110 (2009-07-01), Goldenberg et al.
patent: 0263046 (1988-04-01), None
patent: 0419387 (1991-03-01), None
patent: 0511011 (1992-10-01), None
patent: 0517024 (1992-12-01), None
patent: 0623675 (1994-11-01), None
patent: 921782 (1992-12-01), None
patent: 9604313 (1996-02-01), None
patent: 9808875 (1998-03-01), None
patent: 9966951 (1999-12-01), None
patent: 0034317 (2000-06-01), None
Alt et al. “Novel tetravalent and bispecific IgG-like antibody molecules combining single-chain diabodies with the immunoglobulin gammal Fc or CH3 region” FEBS Lett. Jul. 2, 1999; 454(1-2):90-4.
Arano et al. “Reassessment of Diethylenetriaminepentaacetic Acid (DTPA) as a Chelating Agent for Indium-111 Labeling of Polypeptides Using a Newly Synthesized Monoreactive DTPA Derivative” J. Med. Chem. 1996, 39, 3451-3460.
Bamias and Epenetos “Two-Step Strategies for the Diagnosis and Treatment of Cancer with Bioconjugates” Antibody, Immunoconj. Radiopharm., 5(4):385-395, 1992.
Barbet et al. “Radioimmunotherapy of LS174T Colon Carcinoma in Nude Mice Using an Iodine-131-Labeled Bivalent Hapten Combined with an Anti-CEA x Anti-Indium-DTPA Bispecific Antibody” Tumor Biology, 18 (Suppl. 2), p. 31 (1997).
Barbet et al. “Radioimmundetection of medullary thyroid carcinoma using Indium-111 bivalent hapten and Anti-CEA x Anti-DTPA-Indium bispecific antibody” J. Nucl. Med. Jul. 1998; 39(7):1172-8.
Bardies et al. “Bispecific antibody and Iodine-131-labeled bivalent hapten dosimetry in patients with medullary thyroid or small-cell lung cancer” J. Nucl. Med. Nov. 1996; 37(11):1853-9.
Boden et al. “Preliminary Study of the Metal Binding Site of an Anti-DTPA-Indium Antibody by Equilibrium Binding Immunoassays and Immobilized Metal Ion Affinity Chromatography” Bioconjugate Chem. 1995, 6, 373-379.
Bos et al. “In Vitro Evaluation of DNA-DNA Hybridization as a Two-Step Approach in Radioimmunotherapy of Cancer” Cancer Res. 54, 3479-3486, Jul. 1, 1994.
Bosslet et al. “Generation of Bispecific Monoclonal Antibodies for Two Phase Radioimmunotherapy” Br. J. Cancer May 1991; 63(5):681-6.
Chatziioannou et al. “MICROPET I: Performance Evaluation of a Very High Resolution PET Scanner for Imaging Small Animals” J. Nucl. Med. 38(5), May 1997 Suppl., No. 19, p. 7P-8P.
Cruse and Lewis, Illustrated Dictionary of Immunology, CRC Press, 1995, p. 117.
De Boisferon et al. “Enhanced Targeting Specificity to Tumor Cells by Simultaneous Recognition of Two Antigens” Bioconj. Chem. 2000, 11, 452-460.
De Jonge et al. Production and Characterization of Bispecific Single-Chain Antibody Fragments Mol. Immunol. 32 (17/18)1405-1412 (1995).
Dubel et al. “Reconstitution of human pancreatic RNase from two separate fragments fused to different single chain antibody fragments: on the way to binary immunotoxins” Tumor Targeting (1999) 4, 37-46.
Gautherot et al. “Radioimmunotherapy of LS174T Colon Carcinoma in Nude Mice Using an Iodine-131-Labeled Bivalent Hapten Combined with an Anti-CEA x Anti-Indium-DTPA Bispecific Antibody” J. Nucl. Med. 38(5), May 1997 Suppl., No. 18, p. 7P.
Gautherot et al. “Delivery of therapeutic doses of radioiodine using bispecific antibody-targeted bivalent haptens” J. Nucl. Med. Nov. 1998; 39(11):1937-43.
Gautherot et al. “Therapy for colon carcinoma xenografts with bispecific antibody-targeted, iodine-131-labeled bivalent hapten” Cancer Dec. 15, 1997; 80(12 Suppl.):2618-23.
Gold et al. “Murine Monoclonal Antibodies to Colon-specific Antigen p1” Cancer Res. 50, 6405-6409, Oct. 1, 1990.
Goodwin et al. “Pre-targeted immunoscintigraphy of murine tumors with Indium-111-labeled bifunctional haptens” J. Nucl. Med. Feb. 1988; 29(2):226-34.
Greenwood et al. “The Preparation of 131I-Labelled Human Growth Hormone of High Specific Radioactivity” Biochem. J. (1963) 89, 114-123.
Hayden et al. “Single-chain mono- and bispecific antibody derivatives with novel biological properties and antitumour activity from a COS cell transient expression system” Therapeutic Immunology 1994, 1, 3-15.
Hawkins et al. “Delivery of radionuclides to pretargeted monoclonal antibodies using dihydrofolate reductase and methotrexate in an affinity system” Cancer Res. May 15, 1993; 53(10 Suppl.):2368-73.
Hosono et al. “Biodistribution and dosimetric study in medullary thyroid cancer xenograft using bispecific antibody and Iodine-125-labeled bivalent hapten” J. Nucl. Med. Sep. 1998; 39(9):1608-13.
Kaneko et al. “New Hydrazone Derivatives of Adriamycin and Their Immunoconjugates-a Correlation between Acid Stability and Cytotoxicity” Bioconj. Chem. 2(3):133-141 (1991).
Karacay et al. “Experimental Pretargeting Studies of Cancer with a Humanized anti-CEA x Murine anti-[In-DTPA] Bispecific Antibody Constructs and a 99mTc-/188Re-Labeled Peptide” Bioconj. Chem. 2000, 11, 842-854.
Karacay et al. “Pretargeting Studies with a Murine Anti-Colon-Specific Antigen-P (CSAp) x Chimeric Anti-[IndiumDTPA] Bispecific Antibody and Technetium-99m-Labeled Peptide” Cancer Biother. Radiopharm. 15(4):412 (2000).
Kipriyanov et al. “Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokineti
Goldenberg David M.
Hansen Hans J.
McBride William J.
Immunomedics Inc.
Nakashima Richard A.
Saunders David A
LandOfFree
Production and use of novel peptide-based agents with... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Production and use of novel peptide-based agents with..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Production and use of novel peptide-based agents with... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2707162